Crescent Park Management L.P. lifted its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 8.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,862,482 shares of the company's stock after buying an additional 142,534 shares during the period. Cellebrite DI makes up about 15.7% of Crescent Park Management L.P.'s holdings, making the stock its 2nd biggest holding. Crescent Park Management L.P. owned 0.90% of Cellebrite DI worth $41,030,000 at the end of the most recent reporting period.
Several other large investors have also made changes to their positions in CLBT. True Wind Capital Management L.P. lifted its stake in shares of Cellebrite DI by 18.2% in the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after acquiring an additional 2,130,386 shares in the last quarter. FMR LLC grew its position in shares of Cellebrite DI by 136.3% during the third quarter. FMR LLC now owns 5,616,757 shares of the company's stock worth $94,586,000 after buying an additional 3,239,307 shares in the last quarter. Pertento Partners LLP increased its stake in shares of Cellebrite DI by 26.7% in the fourth quarter. Pertento Partners LLP now owns 2,975,374 shares of the company's stock worth $65,547,000 after buying an additional 626,373 shares during the last quarter. Pembroke Management LTD increased its stake in shares of Cellebrite DI by 4.4% in the fourth quarter. Pembroke Management LTD now owns 1,992,432 shares of the company's stock worth $43,893,000 after buying an additional 84,087 shares during the last quarter. Finally, Principal Financial Group Inc. acquired a new stake in Cellebrite DI in the third quarter valued at $23,402,000. 45.88% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
A number of equities analysts recently commented on the company. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 11th. Needham & Company LLC reiterated a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a research report on Wednesday, April 2nd. Finally, Lake Street Capital boosted their price target on Cellebrite DI from $17.00 to $26.00 and gave the company a "buy" rating in a report on Friday, February 14th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $23.43.
Get Our Latest Stock Report on Cellebrite DI
Cellebrite DI Trading Down 0.6 %
CLBT traded down $0.10 during trading on Monday, reaching $17.61. 628,746 shares of the company were exchanged, compared to its average volume of 1,394,639. Cellebrite DI Ltd. has a 52 week low of $10.25 and a 52 week high of $26.30. The stock has a market cap of $4.22 billion, a P/E ratio of -12.75, a PEG ratio of 4.27 and a beta of 1.44. The firm has a 50 day moving average of $20.41 and a 200 day moving average of $19.97.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. As a group, analysts forecast that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.
Cellebrite DI Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Featured Stories
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
